An early Phase 1 study with a FRα-specific CAR T cells (MOv19-4-1BB-CD3ζ) was conducted in ovarian cancer patients (26) and is being re-launched by intraperitoneal delivery (ClinicalTrials.gov identifier: NCT03585764). This evidence concerns the gene FOLR1 and ovarian carcinoma.